CA2666112A1 - Pyrrolydine derivatives as iap inhibitors - Google Patents

Pyrrolydine derivatives as iap inhibitors Download PDF

Info

Publication number
CA2666112A1
CA2666112A1 CA002666112A CA2666112A CA2666112A1 CA 2666112 A1 CA2666112 A1 CA 2666112A1 CA 002666112 A CA002666112 A CA 002666112A CA 2666112 A CA2666112 A CA 2666112A CA 2666112 A1 CA2666112 A1 CA 2666112A1
Authority
CA
Canada
Prior art keywords
methylamino
pyrrolidin
cyclohexyl
ethyl
propionamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666112A
Other languages
English (en)
French (fr)
Inventor
Mark G. Charest
Christine Hiu-Tung Chen
Ming Chen
Zhuoliang Chen
Miao Dai
Feng He
Huangshu Lei
Christopher Straub
Run-Ming David Wang
Leigh Zawel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666112A1 publication Critical patent/CA2666112A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002666112A 2006-10-12 2007-10-10 Pyrrolydine derivatives as iap inhibitors Abandoned CA2666112A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82923406P 2006-10-12 2006-10-12
US60/829,234 2006-10-12
PCT/US2007/080875 WO2008045905A1 (en) 2006-10-12 2007-10-10 Pyrrolydine derivatives as iap inhibitors

Publications (1)

Publication Number Publication Date
CA2666112A1 true CA2666112A1 (en) 2008-04-17

Family

ID=38984426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666112A Abandoned CA2666112A1 (en) 2006-10-12 2007-10-10 Pyrrolydine derivatives as iap inhibitors

Country Status (11)

Country Link
US (1) US8044209B2 (https=)
EP (1) EP2102229B1 (https=)
JP (1) JP5190062B2 (https=)
KR (1) KR20090065548A (https=)
CN (1) CN101595121A (https=)
AU (1) AU2007307763A1 (https=)
BR (1) BRPI0719221A2 (https=)
CA (1) CA2666112A1 (https=)
MX (1) MX2009003834A (https=)
RU (1) RU2009117701A (https=)
WO (1) WO2008045905A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Birドメイン結合化合物
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
PE20110220A1 (es) * 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
NZ577150A (en) * 2006-12-19 2012-04-27 Genentech Inc Imidazopyridine inhibitors of iap
WO2008134679A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
CN102099035A (zh) 2008-05-16 2011-06-15 诺瓦提斯公司 Iap抑制剂的免疫调节
JP2011529962A (ja) 2008-08-02 2011-12-15 ジェネンテック, インコーポレイテッド Iapのインヒビター
JP5693452B2 (ja) * 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション,インコーポレーテッド 特定のキヌレニン−3−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
US20110218211A1 (en) * 2008-08-16 2011-09-08 Genentech, Inc. Azaindole inhibitors of iap
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US20120040974A1 (en) * 2008-08-18 2012-02-16 Yale University Mif modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
PT2611797T (pt) * 2010-08-31 2017-02-07 Hanmi Science Co Ltd Derivados de quinolina ou de quinazolina com atividade indutora de apoptose nas células
EP2651917A1 (en) * 2010-12-13 2013-10-23 Novartis AG Dimeric iap inhibitors
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
JP2014094886A (ja) * 2011-02-28 2014-05-22 Nippon Chemiphar Co Ltd Gpr119作動薬
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
MX2014001088A (es) * 2011-07-28 2015-03-19 Chdi Foundation Inc Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
KR20140072037A (ko) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
NO2755614T3 (https=) 2012-01-03 2018-03-31
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
JP6321020B2 (ja) * 2012-10-19 2018-05-09 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 二環式複素環化合物およびそれらの治療での使用
GB201218864D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
KR20170004160A (ko) * 2015-07-01 2017-01-11 엘지전자 주식회사 이동단말기 및 그 제어방법
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
BR112020009369A2 (pt) 2017-11-13 2020-10-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd miméticos de smac usados como inibidores de iap e seus usos
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
EP3936126A4 (en) * 2019-03-07 2022-12-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. COMBINATION OF IAP INHIBITOR AND IMMUNOCHECK POINT INHIBITOR
KR20220006611A (ko) * 2019-05-10 2022-01-17 치아타이 티안큉 파마수티컬 그룹 주식회사 Iap 억제제로서의 smac 모방물의 결정 및 그 제조방법
JP7764027B2 (ja) 2019-07-31 2025-11-05 ファイメクス株式会社 複素環化合物
CN112521372B (zh) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 一种细胞凋亡蛋白抑制剂及其制备方法和用途
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020025959A (ko) 2000-05-23 2002-04-04 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 및 이의 용도
WO2004007529A2 (en) * 2002-07-15 2004-01-22 The Trustees Of Princeton University Iap binding compounds
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
DK2253614T3 (da) 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
KR100984459B1 (ko) * 2004-07-02 2010-09-29 제넨테크, 인크. Iap의 억제제
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂

Also Published As

Publication number Publication date
JP5190062B2 (ja) 2013-04-24
CN101595121A (zh) 2009-12-02
BRPI0719221A2 (pt) 2014-03-18
EP2102229A1 (en) 2009-09-23
JP2010506847A (ja) 2010-03-04
RU2009117701A (ru) 2010-11-20
MX2009003834A (es) 2009-04-22
AU2007307763A1 (en) 2008-04-17
US8044209B2 (en) 2011-10-25
WO2008045905A1 (en) 2008-04-17
KR20090065548A (ko) 2009-06-22
EP2102229B1 (en) 2014-03-26
US20110015232A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
EP2102229B1 (en) Pyrrolydine derivatives as iap inhibitors
CA2658525C (en) Smac peptidomimetics useful as iap inhibitors
KR20130140219A (ko) C형 간염 바이러스 복제의 억제제
AU2006255084A1 (en) Organic compounds
AU2007332861A1 (en) 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases
HK1176613B (en) Intermediate compounds for preparing smac peptidomimetics
HK1127616B (en) Smac peptidomimetics useful as iap inhibitors
HK1176612A (en) Organic compounds
AU2014200550A1 (en) Inhibitors of hepatitis C virus replication

Legal Events

Date Code Title Description
FZDE Discontinued